How to Manage High Atrial Rate Events Detected in ICD
Atrial tachyarrhythmia in ICD recipient

• Atrial fibrillation is a very common arrhythmia in patients who need an ICD.
  – About 20% at the time of implantation
  – 50% of patients may develop atrial fibrillation during ICD life span.

Atrial tachyarrhythmia in ICD recipient

• Main Cause of Inappropriate Shock

• Paroxysmal AT/AF beget VT/VF

• Asymptomatic AF detected by device in high risk patient of thromboembolism
Prognostic Importance of Atrial Fibrillation in Implantable Cardioverter-Defibrillator Patients

C. Jan Willem Borleffs, MD, Johannes B. van Rees, MD, Guido H. van Welsenes, MS, Enno T. van der Velde, PhD, Lieselot van Erven, MD, PhD, Jeroen J. Bax, MD, PhD, Martin J. Schalij, MD, PhD

Leiden, the Netherlands

**Figure 3** Appropriate Device Shock
Kaplan-Meier curve for the occurrence of first appropriate shock in patients without a history of atrial fibrillation (AF) (no AF, black line), paroxysmal AF (green line), persistent AF (orange line), or permanent AF (red line).

**Figure 4** Inappropriate Device Shock
Kaplan-Meier curve for the occurrence of first inappropriate device shock in patients without a history of atrial fibrillation (AF) (no AF, black line), paroxysmal AF (green line), persistent AF (orange line), or permanent AF (red line).
ICD therapy and AT/AF

- Patients with permanent AF exhibited more than double the risk of mortality, appropriate and inappropriate device therapy.
- Patients with paroxysmal or persistent AF did not show a significant increased risk of mortality or appropriate device therapy but demonstrated almost 3 times the risk of inappropriate device therapy.

J Am Coll Cardiol 2010;55:879–85
ICD therapy and AT/AF

• the AF is a marker for worse general cardiac status.

• AF could initiate episodes of ventricular arrhythmias.
Do Atrial Tachyarrhythmias Beget Ventricular Tachyarrhythmias in Defibrillator Recipients?

Kenneth M. Stein, MD, FACC,* David E. Euler, PhD,† Rahul Mehra, PhD,† Karlheinz Seidl, MD,‡ David J. Slotwiner, MD,* Suneet Mittal, MD, FACC,* Steven M. Markowitz, MD, FACC,* Bruce B. Lerman, MD, FACC,* for the Jewel AF Worldwide Investigators

New York, New York; Minneapolis, Minnesota; and Ludwigshafen, Germany

Figure 1. Electrogram (Atip-Vring EGM) recording (0.5 mv/mm) at a chart speed 25 mm/s, showing a typical episode of dual tachycardia in one patient. Upward markers indicate atrial events; downward markers indicate ventricular events. The short triple atrial markers indicate ongoing atrial fibrillation (AF) detection (FD). Intermediate-height ventricular markers (VS) indicate sensed R-waves (VS); short double ventricular markers indicate ventricular fibrillation (VF) sense (FS); short triple markers indicates VF detection (FD). The vertical arrows show atrial activation complexes during device-defined AF. The short horizontal arrows show R-waves with intrinsic conduction. The ventricular rate accelerates abruptly; at the same time there is a change in the morphology of the ventricular electrogram (long horizontal arrow). The median RR interval of this device-defined VF episode was 260 ms.
AT/AF begets VT/VF

• 8.9% of the episodes of ventricular arrhythmia were accompanied by AF.
• Ventricular arrhythmias are evoked by rapid and uncontrolled atrioventricular conduction.
• Atrioventricular nodal conduction pattern preceding ventricular tachyarrhythmia were short-long-short sequences
New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: Results from the MINERVA randomized multicenter international trial

Luigi Padeletti, MD, * Helmut Pürerfellner, MD, † Lluis Mont, MD, ‡ Raymond Tukkie, MD, § Antonis S. Manolis, MD, FHRS, ¶ Renato Ricci, MD, ‡ Giuseppe Inama, MD, # Paolo Serra, MD, ** Mike G. Scheffer, MD, †† Vitor Martins, MD, †‡ Eduardo N. Warman, PhD, §§ Marco Vimercati, MS, ¶¶ Andrea Grammatico, PhD, §§§ Giuseppe Boriani, MD, ††† on behalf of the MINERVA Investigators
• **MVP**
  - **Managed Ventricular Pacing (MVP):** an atrial-based pacing mode that is designed to switch to a dual chamber pacing mode in the presence of AV block and to reduce unnecessary RV pacing.

• **DDDRP**
  - **Atrial Prevention Pacing:** three algorithms of atrial pacing designed to recognize and respond to potentially proarrhythmic intrinsic events that could trigger an AT/AF episode.
  - **Atrial Antitachycardia Pacing (aATP):** low voltage atrial pacing during regular atrial tachyarrhythmia intended to restore sinus rhythm. Reactive ATP re-arms in the event of changes in cycle length rate or regularity and in the event of long duration episodes.
Interval (ms)

Onset: 18 sec  
Detection: 1.0 min  
First ATP: 8.5 hr  
Term.

Time (sec)
Incidence of permanent or persistent AF
Are all AHRE real?
AWARE Trial (N=1642)

• Appropriate: 73%
  – AF – 42%
  – Aflutter – 27%
  – Atrial Tachycardia – 4%
• Inappropriate: 27%
  – RNRVAS – 17%
  – Noise – 5%
  – Farfield R-wave oversensing – 3%
  – Sinus tachycardia – 2%
Management of AT/AF in ICD pt

• AT/AF is associated with higher mortality and ICD therapy in ICD pt
• Antiarrhythmic Drug for AT/AF
• ICD therapy programming with prolonged detection and higher rate cut off is necessary to avoid inappropriate therapy
• ICD with ATP for AT/AF
• AF ablation for AT/AF induced VT/VF ?
AF and cryptogenic stroke

• “clinically unrecognized and asymptomatic AF as a potentially important cause of stroke,”
AF and cryptogenic stroke

- The CRYSTAL-AF (CRYptogenic Stroke and underlying Atrial Fibrillation) trial
  - a prospective, randomized, multicenter, global study, in which long-term cardiac monitoring using an ICM for detection of AF in 441 patients with cryptogenic stroke.
  - AF was detected in 8.9% of ICM patients (compared to 1.4% in the ECG control group) at 6 months.
  - long-term follow-up at 3 years, AF was detected in 30% of patients by ICM, compared to only 3% in the conventional ECG group
### Incidence of CIED-detected SCAF

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>CIED</th>
<th>Incidence of AF</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRENDS ¹</td>
<td>2010</td>
<td>PM/ICD</td>
<td>28%</td>
</tr>
<tr>
<td>TRENDS ²</td>
<td>2012</td>
<td>PM/ICD</td>
<td>30%</td>
</tr>
<tr>
<td>ASSERT I ³</td>
<td>2012</td>
<td>PM/ICD</td>
<td>34.7%</td>
</tr>
<tr>
<td>HEALEY ⁴</td>
<td>2013</td>
<td>PM</td>
<td>55.3%</td>
</tr>
<tr>
<td>CRYSTAL-AF ⁵</td>
<td>2014</td>
<td>ILR</td>
<td>12.4%</td>
</tr>
<tr>
<td>IMPACT ⁶</td>
<td>2015</td>
<td>ICD</td>
<td>34.8%</td>
</tr>
<tr>
<td>ASSERT II ⁷</td>
<td>2016</td>
<td>ILR</td>
<td><strong>34.4%</strong></td>
</tr>
</tbody>
</table>
CIED-detected AHREs and Stroke Risk

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>TE EVENT RATE</th>
<th>HAZARD RATIO</th>
</tr>
</thead>
<tbody>
<tr>
<td>ITALIAN REGISTRY</td>
<td>2005</td>
<td>1.2%/YR</td>
<td>3.1</td>
</tr>
<tr>
<td>TRENDS</td>
<td>2009</td>
<td>1.2% OVERALL</td>
<td>2.2</td>
</tr>
<tr>
<td>CRT- REMOTE</td>
<td>2012</td>
<td>2.0% OVERALL</td>
<td>9.4</td>
</tr>
<tr>
<td>ASSERT I</td>
<td>2012</td>
<td>1.69%/YR</td>
<td>2.5</td>
</tr>
<tr>
<td>SOS</td>
<td>2014</td>
<td>0.39%/YR</td>
<td>2.1</td>
</tr>
<tr>
<td><strong>ASSERT II</strong></td>
<td><strong>2016</strong></td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

- ASSERT II:
  - CHA$_2$DS$_2$-VASc=4.14±1.36

- Most patients with implanted devices who experience ischemic stroke do not have AF immediately preceding the stroke
Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT

Isabelle C. Van Gelder¹*, Jeff S. Healey², Harry J.G.M. Crijns³, Jia Wang², Stefan H. Hohnloser⁴, Michael R. Gold⁵, Alessandro Capucci⁶, Chu-Pak Lau⁷, Carlos A. Morillo², Anne H. Hobbelt¹, Michiel Rienstra¹, and Stuart J. Connolly²

¹Department of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands; ²Population Health Research Institute, McMaster University, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada; ³Department of Cardiology, Maastricht University Medical Centre, Cardiovascular Research Institute Maastricht (CARIM), P. Debyelaan 25, 6202 AZ Maastricht, The Netherlands; ⁴Department of Cardiology, J.W. Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany; ⁵Division of Cardiology, Medical University of South Carolina, 114 Doughty Street, MSC 592, Charleston, SC 29425-5920, USA; ⁶Clinica di Cardiologia, Università Politecnica delle Marche, Via Conca 71, Ancona 60126, Italy; and ⁷Cardiology Division, Queen Mary Hospital, University of Hong Kong, 102 Pokfulam Road, Hong Kong SAR, China

Received 1 June 2016; revised 23 September 2016; editorial decision 20 January 2017; accepted 24 January 2017; online publish-ahead-of-print 1 March 2017

See page 1345 for the editorial comment on this article (doi: 10.1093/eurheartj/ehx122)
Summarizing Figure: SCAF >24 h is associated with comparable risk of ischemic stroke and systemic embolism as clinical AF. In this figure the hazard ratio from time dependent Cox model (long term effect, red) and the risk rate from the landmark analysis (blue) of ischemic stroke and systemic embolism are depicted.
Significant AHR episode

• The risk of ischemic stroke or systemic embolism in patients with SCAF between 6 min and 24 h was not significantly different from patients without SCAF.

• SCAF >24 h is associated with an increased risk of ischemic stroke or systemic embolism.
AHE episode in ICD pt

• Time relation to AF development and thromboembolism is unclear.

• According to CHA2DS2-VASc score, AHR episode duration >24 hr should be considered anticoagulation.
감사합니다.